title: Acute hyperglycemia alters the ability of the normal beta-cell to sense and respond to glucose.
abstract: Impaired glucose tolerance (IGT) and non-insulin-dependent diabetes mellitus (NIDDM) are associated with an impaired ability of the beta-cell to sense and respond to small changes in plasma glucose. The aim of this study was to establish whether acute hyperglycemia per se plays a role in inducing this defect in beta-cell response. Seven healthy volunteers with no family history of NIDDM were studied on two occasions during a 12-h oscillatory glucose infusion with a periodicity of 144 min. Once, low-dose glucose was infused at a mean rate of 6 mg x kg(-1) x min(-1) and amplitude 33% above and below the mean rate, and, once, high-dose glucose was infused at 12 mg x kg(-1) x min(-1) and amplitude 16% above and below the mean rate. Mean glucose levels were significantly higher during the high-dose compared with the low-dose glucose infusion [9.5 +/- 0.8 vs. 6.8 +/- 0.2 mM (P < 0.01)], resulting in increased mean insulin secretion rates [ISRs; 469.1 +/- 43.8 vs. 268.4 +/- 29 pmol/min (P < 0.001)] and mean insulin levels [213.6 +/- 46 vs. 67.9 +/- 10.9 pmol/l (P < 0.008)]. Spectral analysis evaluates the regularity of oscillations in glucose, insulin secretion, and insulin at a predetermined frequency. Spectral power for glucose, ISR, and insulin was reduced during the high-dose glucose infusion [11.8 +/- 1.4 to 7.0 +/- 1.6 (P < 0.02), 7.6 +/- 1.5 to 3.2 +/- 0.5 (P < 0.04), and 10.5 +/- 1.6 to 4.6 +/- 0.7 (P < 0.01), respectively]. In conclusion, short-term infusion of high-dose glucose to obtain glucose levels similar to those previously seen in IGT subjects results in reduced spectral power for glucose, ISR, and insulin. The reduction in spectral power previously observed for ISR in IGT or NIDDM subjects may be due partly to hyperglycemia.
authors.affiliation: Clinical Research Unit for Gastrointestinal Endocrinology, Department of Internal Medicine, Philipps University, 35033 Marburg, Germany.
authors.forename: Jürgen
authors.initials: J
authors.lastname: Meyer
authors.forename: Jeppe
authors.initials: J
authors.lastname: Sturis
authors.forename: Martin
authors.initials: M
authors.lastname: Katschinski
authors.forename: Rudolf
authors.initials: R
authors.lastname: Arnold
authors.forename: Burkhard
authors.initials: B
authors.lastname: Göke
authors.forename: Maria M
authors.initials: MM
authors.lastname: Byrne
mesh_terms: D000328:Adult; D001786:Blood Glucose / Q000032:analysis; D005947:Glucose / Q000008:administration & dosage / Q000494:pharmacology*; D018149:Glucose Intolerance / Q000503:physiopathology; D006801:Humans; D006943:Hyperglycemia / Q000503:physiopathology*; D007262:Infusions, Intravenous; D007328:Insulin / Q000378:metabolism*; D000078790:Insulin Secretion; D007515:Islets of Langerhans / Q000187:drug effects* / Q000378:metabolism*; D007700:Kinetics; D008297:Male; D010507:Periodicity
chemical_list: D001786:Blood Glucose; D007328:Insulin; D005947:Glucose